HomeBUSINESS
BUSINESS

Lilly Japan Sales Up 7% in 2017, Upbeat Biz Fueled by Global Simultaneous Development
(Mar.23.2018)

Eli Lilly Japan President Patrik Jonsson
Eli Lilly Japan notched up a revenue rise of 7.0% to log 260.1 billion yen in 2017, buoyed by its major antidepressant/painkiller Cymbalta (duloxetine) and cancer drug Cyramza (ramucirumab), the company said on March 22 ...
(LOG IN FOR FULL STORY)